DSpace@İnönü

Our sentinel lymph node experience in patients diagnosed with DCIS and microinvasive breast carcinoma

Basit öğe kaydını göster

dc.contributor.author Bayramoglu, Zeynep
dc.contributor.author Omeroglu, Ethem
dc.contributor.author Koksal, Hande
dc.contributor.author Eryilmaz, Mehmet Ali
dc.contributor.author Unlu, Yasar
dc.date.accessioned 2022-03-16T10:15:14Z
dc.date.available 2022-03-16T10:15:14Z
dc.date.issued 2021
dc.identifier.citation Bayramoglu, Z., Omeroglu, E., Koksal, H., Eryilmaz, M. A., & Unlu, Y. (2021). Our sentinel lymph node experience in patients diagnosed with DCIS and microinvasive breast carcinoma. Annals of Medical Research en_US
dc.identifier.uri http://hdl.handle.net/11616/55980
dc.description.abstract Aim: Along with the increased availability of radiologic imaging methods, early identification of tumor tissue, and patient surveillance programs; ductal carcinoma in situ (DCIS) and microinvasive DCIS became more commonly identified in the tru-cut biopsy specimens and resected samples of patients. Pathological examinations of the excision materials from these patients reveal invasive tumors, microinvasions or DCIS alone. Recently, it has become debatable whether to perform a sentinel lymph node biopsy (SLNB) in patients diagnosed with DCIS or microinvasive DCIS. In this present study, we evaluated the diagnosis made by examining the excision material, any presence of lymph node metastases, and the relationship of hormone profile to the presence of metastases in the patients diagnosed with DCIS or microinvasive DCIS by the examination of tru-cut biopsy specimens. Based on our study results, we discussed the requirement for SLNB in patients with a tru-cut diagnosis of DCIS or microinvasive DCIS. Materials and Methods: The study included 172 patients, who underwent surgical excision and SLNB after receiving a tru-cut biopsy diagnosis of DCIS and microinvasive DCIS in our hospital from the year 2010 to 2018. Results: Tru-cut biopsy diagnoses were DCIS and microinvasive DCIS in 69.8% (120 patients) and 30.2% (52 patients) respectively. SLNB metastases were identified in 35.8% (n=43) of the DCIS positive patients and 44.2% (n=23) in the microinvasive DCIS positive patients. The diagnosis of invasive ductal carcinoma after mastectomy was made at a rate of 90.0% (n=108) among the DCIS positive patients and 92.3% (n=48) among the microinvasive DCIS positive patients. Conclusion: SLNB metastases were found in 35.8% (n=43) and 44.2% (n=23) of the DCIS positive patients and microinvasive DCIS positive patients, respectively. We conclude that SLNB should be favorably proper to perform in the patients with tru-cut diagnoses of DCIS and microinvasive DCIS because a high rate of SLNB metastases was detected in our DCIS and microinvasive DCIS patients and a high rate of invasive ductal carcinoma diagnosis was made after examining the excision material of these patients. en_US
dc.language.iso eng en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.title Our sentinel lymph node experience in patients diagnosed with DCIS and microinvasive breast carcinoma en_US
dc.type article en_US
dc.relation.journal Annals of Medical Research en_US
dc.contributor.department İnönü Üniversitesi en_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster